US OptionsDetailed Quotes
NNVC241220P5000
- 3.86
- 0.000.00%
15min DelayClose Nov 22 16:00 ET
0.00High0.00Low
3.86Open3.86Pre Close0 Volume3 Open Interest5.00Strike Price0.00Turnover0.00%IV14.93%PremiumDec 20, 2024Expiry Date3.66Intrinsic Value100Multiplier25DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.48Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Nanoviricides Stock Discussion
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
NanoViricides (NYSE:NNVC) announces a corporate presentation at the Spartan Capital Investors Conference 2024 on November 4, featuring their lead drug candidate NV-387. The presentation will highlight NV-387's completion of Phase I clinical trials and its demonstrated antiviral activity against multiple viruses including Influenza, RSV, COVID, and MPox/Smallpo...
Accesswire· 4 mins ago
SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American.:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it has now obtained a right of first refusal (ROFR) for all antiviral drug developments from the R&D firm TheraCour Pharma...
NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including "Trojan Horse" Drugs
NanoViricides has signed a Memorandum of Understanding (MoU) with TheraCour Pharma, granting it a right of first refusal (ROFR) for all antiviral drug developments. This agreement, made on September 23, 2024, includes intellectual property rights for developing treatments against any viral infections.
The company's lead drug, NV-387, has shown...
nanoviricides.c...
https://www.nanoviricides.com/Investor%20Info/company-news
MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
NanoViricides (NYSE:NNVC) is investigating the use of its drug candidate NV-387 to treat MPOX under the WHO MEURI protocol, following the recent MPOX outbreak declaration. Key points:
1. NV-387 completed Phase I trials with no adverse events reported.
2. It showed strong survival improvement in animal studies, matching the approved drug tecovirimat.
3. NV-3...
We are growing much more confident in identifying growing companies.
The problem now is, when to take profit? When to re-open position?
For example, we rode $ADMA Biologics (ADMA.US)$ from before earnings to $18 and closed out. Except they will easily be more successful in the future - and have continued running. The balance when it is overbought to the momentum of the trend is tough!!
Another example is $Nanoviricides (NNVC.US)$ : we rode them to their 52-week high ...
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -
A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
NanoViricides is progressing towards a Phase II clinical trial of its drug candidate NV-387, aimed at treating multiple viral infections including RSV, COVID, and Influenza. Dr. Anil Diwan is collaborating with experts to develop a trial plan and protocol. NV-387 has demonstrated strong e...
No comment yet